WO2011111143A1 - Médicament pour l'arthrite rhumatoïde - Google Patents

Médicament pour l'arthrite rhumatoïde Download PDF

Info

Publication number
WO2011111143A1
WO2011111143A1 PCT/JP2010/007262 JP2010007262W WO2011111143A1 WO 2011111143 A1 WO2011111143 A1 WO 2011111143A1 JP 2010007262 W JP2010007262 W JP 2010007262W WO 2011111143 A1 WO2011111143 A1 WO 2011111143A1
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
mtx
bed
day
das28
Prior art date
Application number
PCT/JP2010/007262
Other languages
English (en)
Japanese (ja)
Inventor
秀人 中村
Original Assignee
Nakamura Hideto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nakamura Hideto filed Critical Nakamura Hideto
Publication of WO2011111143A1 publication Critical patent/WO2011111143A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a rheumatoid arthritis drug.
  • the “morning stiffness” is a joint pain of the extremities that appears in the early morning and is the most characteristic symptom of RA that has been known for a long time. Further, it is known that “morning stiffness” is an RA-specific circadian rhythm that does not appear during the day but appears early in the morning. This “morning stiffness” is known to involve various inflammatory cytokines such as IL-6 and TNF- ⁇ . In recent years, inflammatory cytokines have a circadian rhythm, and this circadian rhythm has been reported to show a peak in the early morning corresponding to “morning stiffness” appearing in RA patients (Non-patent Document 1). ).
  • MTX methotrexate
  • Non-patent Document 2 In order to suppress inflammatory cytokines that peak in the early morning, considering the circadian rhythms of inflammatory cytokines and daily living behavior of humans, MTX was changed from an existing administration method to a time treatment that is taken only after dinner. Case reports have also been made that rheumatic symptoms can be improved (Non-patent Document 2).
  • Non-Patent Document 2 the pharmacological effect is insufficient even in the time treatment in which MTX is taken only after dinner. The reason is the difference between the half-life of MTX and the circadian rhythm of inflammatory cytokines. The half-life of MTX is 2 to 4 hours. Even if MTX is taken only after dinner, the maximum allowable amount of MTX is administered for inflammatory cytokines that increase from midnight to early morning However, it did not show a sufficient medicinal effect and did not lead to a significant improvement. Therefore, an object of the present invention is to provide a rheumatoid arthritis drug that is effective in ameliorating and suppressing RA symptoms and effectively suppressing it.
  • the rheumatoid arthritis drug of the present invention has been made based on such findings, and as described in claim 1, is a rheumatoid arthritis drug containing MTX as an active ingredient, and is administered to a rheumatoid arthritis patient before going to bed. It is used so that it may be used.
  • the rheumatoid arthritis drug according to claim 2 is the rheumatoid arthritis drug according to claim 1, characterized in that the administration is at night.
  • the rheumatoid arthritis drug according to claim 3 is the rheumatoid arthritis drug according to claim 2, wherein the administration is from 9:00 pm to 3:00 am.
  • the rheumatoid arthritis drug containing MTX of the present invention is administered before bedtime according to the circadian rhythm of inflammatory cytokines, thereby maintaining RA safety without changing the dose and the number of administration, In particular, joint pain can be reduced. In addition, a delayed effect of RA severity and clinical remission can be obtained. In addition, excessive administration of MTX can be prevented, and the burden on the patient's body and treatment costs can be reduced.
  • DAS Disease Activity Score
  • the rheumatoid arthritis drug of the present invention is a drug containing MTX as an active ingredient, and is used as a tablet, capsule or the like.
  • the rheumatoid arthritis drug of the present invention is used so that it is administered before going to bed. Specifically, for example, it may be administered once a day before going to bed, administered before going to bed on the first day, before going to bed on the second day, before going to bed on the third day, and for the remaining 4 days. This is repeated every week.
  • the rheumatoid arthritis drug of the present invention is administered from 9 pm to 3 am before bedtime, and more preferably from 1 am to 3 am.
  • Inflammatory cytokines have a circadian rhythm that increases from midnight (2 am) to early morning (5 am). By taking MTX during this time period, the concentration of MTX in the blood is increased during this time period. This is because if it can be maintained, an increase in inflammatory cytokines can be suppressed, and morning stiffness can be suppressed.
  • the effective dose of MTX is preferably 4 to 20 mg per week.
  • MTX is administered at 4 mg / week.
  • 6 mg / week or more for patients who do not achieve a sufficient effect, 6 mg / week or more, and a maximum of 8 mg / week is administered.
  • MTX is administered at 7.5 to 20 mg / week for RA patients.
  • the effective dose of MTX refers to a dose at which MTX is effective in patients with rheumatoid arthritis.
  • the effect of MTX is judged by the fact that administration of MTX alleviates symptoms such as joint pain and swelling in individual patients.
  • MTX has already been administered as a treatment for RA in RA patients over 20 years old who have been admitted to the medical corporation White Cross Society Sasebo Central Hospital.
  • the subjects were 17 patients with a DAS28 of 3.2 or more showing disease activity of RA and currently not using biologics.
  • the breakdown of the 17 subjects is 5 males and 12 females, the average duration of RA is 11.8 years (2 years (minimum) -33 years (maximum)), and the average age is 61.0. He was 42 years old (minimum)-78 years old (maximum).
  • DAS28 0.56 ⁇ (T28) 1/2 + 0.28 ⁇ (S28) 1/2 + 0.36 ⁇ ln (CRP + 1) + 0.014 ⁇ GH + 0.96 T28 and S28 palpate 28 joints such as hands, elbows, and shoulders, T28 is the number of tender joints (the number of joints that are painful when pressed), and S28 is the number of swollen joints (swelling Number of joints) ”.
  • C-reactive protein is a protein that measures the degree of inflammation by blood sampling. If inflammation or tissue destruction occurs in the body, it is a protein that appears in blood. The stronger the inflammation, the higher the value.
  • GH is a self-assessment of the general condition performed by a patient. On a 100 mm scale called VAS (Visual analog scale), 0 is “very good (no symptoms)”, 100 is “very bad” ", It is the value that the patient indicates. The value calculated by the above formula was evaluated in four stages: high disease activity (high disease activity), moderate disease activity (moderate disease activity), low disease activity (low disease activity), and clinical remission.
  • the therapeutic effect is good (good response), moderate (moderate response), and no response (invariant). It was evaluated in three stages.
  • the value (X) of the disease activity evaluation by DAS28 is “high disease activity” when X> 5.1, “moderate disease activity” when 3.2 ⁇ X ⁇ 5.1, and X ⁇ 3. 2 means “low disease activity” and X ⁇ 2.6 means “clinical remission”.
  • Table 1 since the value (X) of DAS28 was higher at the start of chronotherapy than that of 2 months before the start of chronotherapy, RA symptoms worsened. In DAS28 at the start of chronotherapy, the average value was 3 .83 (3.25 (minimum) -5.30 (maximum)), moderately active disease, and slightly elevated rheumatic symptoms.
  • the average value of DAS28 decreased from one month after chronotherapy, and the average value of DAS28 three months after the start of chronotherapy was 3.31, indicating that although the disease was moderately active, the symptoms of RA were reduced. confirmed.
  • Table 1 and FIG. 1 in the time treatment in which MTX is administered before going to bed, the therapeutic effect appears from one month after the start of the time treatment, and the average value of DAS28 is the first month compared with that before the start of the time treatment. 0.462 at the second month, 0.506 at the second month, and 0.521 at the third month.
  • Table 2 shows the results of the effectiveness evaluation of MTX according to the EULAR improvement criteria.
  • the criteria in Table 2 are the values of the difference in DAS28 (Y) after changing the MTX administration time (after 3 months) relative to DAS28 before changing the MTX administration time (at the start of chronotherapy). This means that the effect of chronotherapy with MTX is “moderate response” when 0.6> Y, and “invariant” when Y ⁇ 0.6, that is, no improvement was observed. It was confirmed that 7 of 17 cases (41.2%) improved to show a moderate response, and of these 4 cases (23.5%) reached clinical remission in DAS28.

Abstract

L'invention porte sur un médicament pour l'arthrite rhumatoïde qui est efficace pour le soulagement et la suppression des symptômes de l'arthrite rhumatoïde. Le médicament pour l'arthrite rhumatoïde supprime efficacement les symptômes de l'arthrite rhumatoïde. De manière spécifique, l'invention porte sur un médicament pour l'arthrite rhumatoïde qui contient du méthotrexate en tant que principe actif et est caractérisé en ce que le méthotrexate est administré au coucher.
PCT/JP2010/007262 2010-03-12 2010-12-15 Médicament pour l'arthrite rhumatoïde WO2011111143A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010056428A JP2011190199A (ja) 2010-03-12 2010-03-12 関節リウマチ薬
JP2010-056428 2010-03-12

Publications (1)

Publication Number Publication Date
WO2011111143A1 true WO2011111143A1 (fr) 2011-09-15

Family

ID=44562991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/007262 WO2011111143A1 (fr) 2010-03-12 2010-12-15 Médicament pour l'arthrite rhumatoïde

Country Status (2)

Country Link
JP (1) JP2011190199A (fr)
WO (1) WO2011111143A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201040A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc. Suspension d'enzyme activée par l'eau
WO2016201044A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc Produits encapsulés osmotiques à éclatement
WO2016201069A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc Particules contenant une enzyme basse densité
WO2018183662A1 (fr) 2017-03-31 2018-10-04 Danisco Us Inc Formulations d'enzyme à libération retardée pour détergents contenant un agent de blanchiment
WO2019006077A1 (fr) 2017-06-30 2019-01-03 Danisco Us Inc Particules contenant une enzyme à faible agglomération
WO2019125683A1 (fr) 2017-12-21 2019-06-27 Danisco Us Inc Granulés thermofusibles contenant des enzymes, comprenant un déshydratant thermotolérant
WO2019156670A1 (fr) 2018-02-08 2019-08-15 Danisco Us Inc. Particules de matrice de cire résistant à la chaleur pour encapsulation d'enzymes
WO2020047215A1 (fr) 2018-08-30 2020-03-05 Danisco Us Inc Granulés contenant des enzymes
CN113795250A (zh) * 2019-05-10 2021-12-14 西奈克制药有限公司 关节炎疾病的联合治疗
WO2023039270A2 (fr) 2021-09-13 2023-03-16 Danisco Us Inc. Granulés contenant un agent bioactif

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIDETO FUJI: "Ko Rheumatism-yaku no Jikan Chiryo eno Tenbo", JOURNAL OF CHRONOBIOLOGY, vol. 15, no. 2, 2009, pages 33 - 39 *
HIDETO FUJI: "Ko Rheumatism-yaku no Jikan Yakubutsu Ryoho o Mezashite", SHUKAN YAKUJI SHINPO, vol. 2610, 1 January 2010 (2010-01-01), pages 6 - 12 *
TO,H. ET AL., THE JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 61, no. 10, 2009, pages 1333 - 8 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201040A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc. Suspension d'enzyme activée par l'eau
WO2016201044A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc Produits encapsulés osmotiques à éclatement
WO2016201069A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc Particules contenant une enzyme basse densité
WO2018183662A1 (fr) 2017-03-31 2018-10-04 Danisco Us Inc Formulations d'enzyme à libération retardée pour détergents contenant un agent de blanchiment
WO2019006077A1 (fr) 2017-06-30 2019-01-03 Danisco Us Inc Particules contenant une enzyme à faible agglomération
WO2019125683A1 (fr) 2017-12-21 2019-06-27 Danisco Us Inc Granulés thermofusibles contenant des enzymes, comprenant un déshydratant thermotolérant
WO2019156670A1 (fr) 2018-02-08 2019-08-15 Danisco Us Inc. Particules de matrice de cire résistant à la chaleur pour encapsulation d'enzymes
WO2020047215A1 (fr) 2018-08-30 2020-03-05 Danisco Us Inc Granulés contenant des enzymes
CN113795250A (zh) * 2019-05-10 2021-12-14 西奈克制药有限公司 关节炎疾病的联合治疗
WO2023039270A2 (fr) 2021-09-13 2023-03-16 Danisco Us Inc. Granulés contenant un agent bioactif

Also Published As

Publication number Publication date
JP2011190199A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
WO2011111143A1 (fr) Médicament pour l'arthrite rhumatoïde
Stevens et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
JP6313414B2 (ja) 外傷性傷害の処置におけるレボセチリジン及びモンテルカストの使用
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
EA034864B1 (ru) Способ лечения эозинофильной астмы со степенью тяжести от умеренной до тяжёлой
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
EP1471916B1 (fr) Traitement de la polyarthrite rhumatoide avec imatinib
Bhansing et al. Gout: a clinical syndrome illustrated and discussed.
Farshidi et al. Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C
CN111821423A (zh) 一种白介素2用于治疗慢性自发性荨麻疹的应用
Fava et al. Single Nightly Administration of Ketoprofen (Orudis®) and Indomethacin Suppositories in the Management of Osteoarthritis: A Double-Blind Trial
Münzel et al. Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination
Shukla et al. Successful management and withdrawal of conventional medicine in Amavata patient (Seropositive Rheumatoid Arthritis) with an Ayurvedic intervention: A Case Report
WO2021104034A1 (fr) Utilisation de la 4-hydroxybenxaldéhyde dans le traitement d'affections abdominales inflammatoires
Hsu et al. M201 should FENO be used as a biomarker to measure response to benralizumab?
Hoang et al. Zinc Iodide-Dimethyl Sulfoxide Composition in Treatment of Chronic Respiratory Diseases
Pillarisetty et al. FRI0609 EXPERIENCE WITH BIOLOGIC AGENTS FOR THE TREATMENT OF CARDIAC SARCOIDOSIS IN A US ACADEMIC MEDICAL CENTER
Kalaidina et al. M200 ON PINS AND NEEDLES: RECOGNIZING NEUROPATHY AS FIRST CLINICAL MANIFESTATION OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Silverman M202 TREATMENT OF COUGH/COLD SYMPTOMS WITH SECOND GENERATION ANTIHISTAMINE, LEVOCETIRIZINE WITH INCREASED SAFETY AND RAPID RESPONSE
Li et al. Efficacy of H1 receptor antagonist plus pregabalin capsules in skin pruritus: A controlled study
JP5699030B2 (ja) エタネルセプトを含む線維筋痛症の治療剤
Ambanelli et al. Indoprofen in rheumatic patients with acute episodes: a multicentre trial
Monteagudo et al. AB0388 Risk of Non Adherence To Oral Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. ARCO Study
Goldbach-Mansky et al. A pilot study to evaluate the safety and efficacy of the long-acting IL-1 inhibitor, rilonacept (IL-1 Trap) in patients with familial cold autoinflammatory syndrome (FCAS)
Anno et al. SAT0136 Patients with Rheumatoid Arthritis and High Levels of Anti-Cyclic Citrullinated Peptide Antibody under Treatment with High-Dose Glucocorticoid Frequently Fall: Five-Year Findings of The Tomorrow Study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10847376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 20/11/2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10847376

Country of ref document: EP

Kind code of ref document: A1